GET DAILY SIGNALSWhy Is Evaxion Biotech (EVAX) Stock Down -9.67% Today?
Key Takeaways
- EVAX shares fell roughly 9.67% to about $2.71, down from a prior-session close of $3.00.
- The primary catalyst was an amended SEC registration filing tied to the European Investment Bank (EIB) warrant settlement, reviving concerns about potential share overhang.
- Secondary pressure came from profit-taking after Friday's sharp rally, alongside broader weakness in biotech and European ADRs.
- The decline pushed the stock to test its 52-week low of $2.71.
- Traders are watching for the registration statement's effectiveness and any warrant-exercise activity from the EIB.
- For more detail on valuation, results, and projections, explore Price Targets, Earnings, and Forecast pages.
- Discover how automated strategies are positioning across the market by exploring Trending AI Robots.
Opening Summary
Evaxion Biotech A/S (EVAX), a clinical-stage TechBio company developing AI-Immunology™-powered vaccines for cancer and infectious diseases, saw its American depositary receipts slide sharply in Monday's session. The stock fell approximately 9.67% to around $2.71, compared with a prior close of $3.00. The move reversed much of the previous session's advance and was attributed by market participants to a newly filed regulatory amendment tied to a warrant settlement with the European Investment Bank, which rekindled concerns about a potential increase in tradable shares.
Registration Filing Revives Dilution Overhang
The immediate trigger for the selloff was Evaxion's announcement that it had filed an amendment to its Form F-1 registration statement related to its 2025 debt settlement agreement with the European Investment Bank (EIB). Under that agreement, finalized in July 2025, the EIB converted €3.5 million of a €7 million loan into warrants to subscribe for 38,450,000 ordinary shares at an effective conversion price of $4.87 per ADS.
While the company emphasized that it is not conducting a capital raise and will not receive proceeds from any resale, the filing relates to the EIB's potential ability to resell shares issued upon exercise of those warrants. For a small-cap, thinly traded clinical-stage biotech, even the prospect of a large block of shares entering the market can weigh on sentiment, as investors price in the possibility of supply overhang and dilution.
Profit-Taking After a Strong Rally
The decline also reflects a reversal of momentum. On Friday, EVAX had surged roughly 8.7% to close at $3.00, its best level in recent sessions, supported by positive sentiment around its AI-Immunology platform and recent Phase 2 data for its personalized cancer vaccine EVX-01. With no incremental positive catalyst on Monday, traders moved to lock in gains, and the registration-filing news gave sellers a concrete reason to step in.
Market Context and Trading Activity
The move was amplified by the stock's low trading liquidity. Friday's rally occurred on volume of about 120,000 shares, well above the roughly 15,000-to-20,000-share range seen on quieter days earlier in the week. Elevated volume during a down move can signal distribution, while light volume on the upside often leaves rallies vulnerable to sharp retracements. Monday's slide carried EVAX down to its 52-week low of $2.71, a level traders are now watching closely as a technical support zone.
Broader sentiment offered little offset. European American depositary receipts traded mixed-to-lower in the session, with biotech names among the leading decliners, leaving small-cap clinical-stage developers without a sector tailwind.
What Comes Next for EVAX
Looking ahead, investors will monitor whether the registration statement is declared effective and whether the EIB moves to exercise or sell any of its warrants, which could determine the extent of any actual share supply. Beyond the financing mechanics, the company's fundamentals remain tied to its clinical pipeline, including further data on EVX-01 and additional programs such as EVX-04, with presentations expected at upcoming medical meetings.
As a clinical-stage company that remains unprofitable, EVAX carries meaningful risks: ongoing cash burn, the need for future funding, and the inherent uncertainty of clinical development. Any renewed equity offering, adverse trial data, or broader risk-off rotation in speculative biotech could influence the stock further in either direction.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of the platform's strongest-performing automated trading bots under current market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, with strategies that vary by approach, timeframe, performance metrics, and the symbols they trade. Browsing this section can help investors see how algorithmic systems are adapting to shifting market dynamics. Explore the Trending AI Robots page to learn more.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EVAX's RSI Oscillator recovers from overbought zone
The 10-day RSI Oscillator for EVAX moved out of overbought territory on October 21, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 29 instances where the indicator moved out of the overbought zone. In 28 of the 29 cases the stock moved lower in the days that followed. This puts the odds of a move down at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EVAX as a result. In 77 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
The Moving Average Convergence Divergence Histogram (MACD) for EVAX turned negative on October 28, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 41 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.
EVAX moved below its 50-day moving average on October 26, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for EVAX crossed bearishly below the 50-day moving average on November 04, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EVAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EVAX broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 7 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +1.71% 3-day Advance, the price is estimated to grow further. Considering data from situations where EVAX advanced for three days, in 191 of 228 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 89 of 97 cases where EVAX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 24 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.840) is normal, around the industry mean (3.498). P/E Ratio (-6.000) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.452) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 50 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. EVAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EVAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement